Jazz Pharmaceuticals plc - stock earnings
JAZZ Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 1, 2024 AfterMarket | 2.68 / 4.27 | - | 902.0 million / 974.1 million | - |
JAZZ Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | 94.2 million USD | 1.0 billion USD |
| 2023Q3 | 146.8 million USD | 972.1 million USD |
| 2023Q2 | 104.4 million USD | 957.3 million USD |
| 2023Q1 | 69.4 million USD | 892.8 million USD |
| 2022Q4 | -240.0 million USD | 972.1 million USD |
| 2022Q3 | -17.1 million USD | 940.7 million USD |
| 2022Q2 | 34.7 million USD | 932.9 million USD |
| 2022Q1 | 5.8 million USD | 813.7 million USD |
| 2021Q4 | -35.4 million USD | 896.7 million USD |
| 2021Q3 | -52.8 million USD | 838.1 million USD |
| 2021Q2 | -363.3 million USD | 751.8 million USD |
| 2021Q1 | 121.8 million USD | 607.6 million USD |
| 2020Q4 | 133.4 million USD | 665.5 million USD |
| 2020Q3 | 148.2 million USD | 600.9 million USD |
| 2020Q2 | 114.8 million USD | 562.4 million USD |
| 2020Q1 | -157.8 million USD | 534.7 million USD |
| 2019Q4 | 74.0 million USD | 581.7 million USD |
| 2019Q3 | 102.3 million USD | 537.7 million USD |
| 2019Q2 | 261.9 million USD | 534.1 million USD |
| 2019Q1 | 85.2 million USD | 508.2 million USD |
| 2018Q4 | 159.5 million USD | 476.5 million USD |
| 2018Q3 | 149.3 million USD | 469.4 million USD |
| 2018Q2 | 92.3 million USD | 500.5 million USD |
| 2018Q1 | 46.0 million USD | 444.6 million USD |
| 2017Q4 | 232.2 million USD | 436.4 million USD |
| 2017Q3 | 63.5 million USD | 411.9 million USD |
| 2017Q2 | 105.6 million USD | 394.4 million USD |
| 2017Q1 | 86.5 million USD | 376.1 million USD |
| 2016Q4 | 116.7 million USD | 396.6 million USD |
| 2016Q3 | 87.1 million USD | 374.2 million USD |
| 2016Q2 | 111.3 million USD | 381.2 million USD |
| 2016Q1 | 74.1 million USD | 336.0 million USD |
| 2015Q4 | 82.8 million USD | 340.9 million USD |
| 2015Q3 | 88.0 million USD | 340.9 million USD |
| 2015Q2 | 88.1 million USD | 333.7 million USD |
| 2015Q1 | 70.7 million USD | 309.3 million USD |
| 2014Q4 | 81.6 million USD | 328.1 million USD |
| 2014Q3 | 25.8 million USD | 306.6 million USD |
| 2014Q2 | 43.7 million USD | 291.2 million USD |
| 2014Q1 | -92.7 million USD | 246.9 million USD |
| 2013Q4 | 55.3 million USD | 235.8 million USD |
| 2013Q3 | 75.4 million USD | 232.2 million USD |
| 2013Q2 | 42.2 million USD | 208.3 million USD |
| 2013Q1 | 43.4 million USD | 196.2 million USD |
| 2012Q4 | 200.6 million USD | 183.7 million USD |
| 2012Q3 | 33.2 million USD | 175.5 million USD |
| 2012Q2 | 27.1 million USD | 129.5 million USD |
| 2012Q1 | 27.7 million USD | 108.4 million USD |
| 2011Q4 | 37.5 million USD | 83.5 million USD |
| 2011Q3 | 32.5 million USD | 73.3 million USD |
| 2011Q2 | 33.2 million USD | 64.6 million USD |
| 2011Q1 | 21.8 million USD | 50.9 million USD |
| 2010Q4 | 24.5 million USD | 53.4 million USD |
| 2010Q3 | 13.2 million USD | 44.8 million USD |
| 2010Q2 | -6.4 million USD | 40.5 million USD |
| 2010Q1 | 1.5 million USD | 35.2 million USD |
| 2009Q4 | 5.7 million USD | 38.3 million USD |
| 2009Q3 | -1.7 million USD | 30.8 million USD |
| 2009Q2 | 2.2 million USD | 37.3 million USD |
| 2009Q1 | -13.0 million USD | 22.1 million USD |
| 2008Q4 | -56.9 million USD | 19.6 million USD |
| 2008Q3 | -28.8 million USD | 17.7 million USD |
| 2008Q2 | -51.9 million USD | 15.5 million USD |
| 2008Q1 | -46.7 million USD | 14.6 million USD |
| 2007Q4 | -60.0 million USD | 15.5 million USD |
| 2007Q3 | -19.4 million USD | 21.5 million USD |
| 2007Q2 | -39.9 million USD | 14.3 million USD |
| 2007Q1 | -19.6 million USD | 14.1 million USD |
| 2006Q4 | -12.3 million USD | 11.7 million USD |
| 2006Q3 | -12.3 million USD | 11.7 million USD |
| 2006Q2 | -12.3 million USD | 11.7 million USD |
| 2006Q1 | -22.4 million USD | 9.8 million USD |
| 2005Q4 | -21.3 million USD | 5.4 million USD |
| 2005Q3 | -21.3 million USD | 5.4 million USD |
| 2005Q2 | -21.3 million USD | 5.4 million USD |
| 2005Q1 | -21.3 million USD | 5.4 million USD |
JAZZ Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | 414.8 million USD | 3.8 billion USD |
| 2022 | -214.1 million USD | 3.7 billion USD |
| 2021 | -329.0 million USD | 3.1 billion USD |
| 2020 | 238.6 million USD | 2.4 billion USD |
| 2019 | 523.4 million USD | 2.2 billion USD |
| 2018 | 447.1 million USD | 1.9 billion USD |
| 2017 | 487.8 million USD | 1.6 billion USD |
| 2016 | 396.8 million USD | 1.5 billion USD |
| 2015 | 329.5 million USD | 1.3 billion USD |
| 2014 | 58.4 million USD | 1.2 billion USD |
| 2013 | 216.3 million USD | 872.4 million USD |
| 2012 | 288.6 million USD | 586.0 million USD |
| 2011 | 125.0 million USD | 272.3 million USD |
| 2010 | 32.8 million USD | 173.8 million USD |
| 2009 | -6.8 million USD | 128.4 million USD |
| 2008 | -184.3 million USD | 67.5 million USD |
| 2007 | -138.8 million USD | 65.3 million USD |
| 2006 | -59.4 million USD | 44.9 million USD |
| 2005 | -85.2 million USD | 21.4 million USD |
| 2004 | -24.8 million USD | ? USD |
JAZZ
Price: $110.31
52 week price:
Payout Ratio Range:
Earnings Per Share: 6.10 USD
P/E Ratio: 144.80
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 468012
Ebitda: 136.8 millionMarket Capitalization: 7.3 billion